A Study of IBI362 9 mg in Chinese Adults With Obesity

NCT06164873 · Active, not recruiting

Last updated 2026-05-28

This clinical trial tests the effect of the medication IBI362 at a 9 mg dose on body weight in Chinese adults who have obesity.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 462 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-12 · est. completion 2025-09

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06164873 ↗

Description as written by the study sponsor.

This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study evaluating the efficacy and safety of IBI362 9 mg in obese subjects. Subjects will be randomly assigned to IBI362 9 mg and placebo groups. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 2-week screening period, a 60-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.

Treatments tested

IBI362 Drug

Once-weekly injections of gradually increased doses of IBI362
Placebo Drug

Once-weekly injections of volume-matched placebo

Main thing measured	Percent Change from Baseline in Body Weight
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06164873 ↗